“April 2017 : Intensification of the Company’s international development with the appointment of a new CEO : Mrs Nawal Ouzren”
“Sensorion aims to become a major player in the development of inner ear disease treatments of and thus fulfill unmet medical needs”
"Our mission is to develop innovative and targeted treatments for inner ear diseases with vertigo, tinnitus, hearing loss"
" Sensorion, has received “French Tech Pass” certification, and thus joins an exclusive circle of innovative French technology companies with substantial development potential"

Publications

  • Symptomatic treatment of vestibular deficits: therapeutic potential of histamine H4 receptors.
    Wersinger E, Gaboyard-Niay S, Travo C, Soto E, Baez A, Vega R, Brugeaud A, Chabbert C.
    J Vestib Res. 2013;23(3):153-9. Review.
    http://www.ncbi.nlm.nih.gov/pubmed/24177347

  • Ondansetron reduces lasting vestibular deficits in a model of severe peripheral excitotoxic injury.
    Dyhrfjeld-Johnsen J, Gaboyard-Niay S, Broussy A, Saleur A, Brugeaud A, Chabbert C.
    J Vestib Res. 2013;23(3):177-86.  
    http://www.ncbi.nlm.nih.gov/pubmed/24177349

  • Histamine H4 receptor antagonists as potent modulators of mammalian vestibular primary neuron excitability.
    Desmadryl G, Gaboyard-Niay S, Brugeaud A, Travo C, Broussy A, Saleur A, Dyhrfjeld-Johnsen J, Wersinger E, Chabbert C.
    Br J Pharmacol. 2012 Oct; 167(4):905-16.
    http://www.ncbi.nlm.nih.gov/pubmed/22624822